Royal Bank Of Canada Acorda Therapeutics Inc Transaction History

Royal Bank Of Canada

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.55 - $1.0 $3 - $6	6 Added 1.86%	329 $0
Q4 2022 Feb 14, 2023	SELL	$0.52 - $0.77 $7 - $10	-14 Reduced 4.15%	323 $0
Q3 2022 Nov 14, 2022	BUY	$0.29 - $0.53 $12 - $23	44 Added 15.02%	337 $0
Q2 2022 Aug 15, 2022	SELL	$0.3 - $1.67 $12 - $71	-43 Reduced 12.8%	293 $0
Q1 2022 May 16, 2022	SELL	$1.61 - $2.5 $899 - $1,397	-559 Reduced 62.46%	336 $0
Q4 2021 Feb 14, 2022	BUY	$2.3 - $4.71 $1,481 - $3,033	644 Added 256.57%	895 $3,000
Q3 2021 Nov 15, 2021	SELL	$3.36 - $4.79 $651 - $929	-194 Reduced 43.6%	251 $1,000
Q2 2021 Aug 16, 2021	BUY	$3.61 - $5.23 $1,606 - $2,327	445 New	445 $2,000

133K

Ticker ACOR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 24,338,400
Market Cap $6.33M
Description
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.